BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AusAm Biotechnologies Release: International Diabetes FederationSupports First-of-Its-Kind International Symposium On Albuminuria


10/19/2005 5:11:00 PM

Medical Professionals Gather to Discuss the Important Role of the Protein Albumin in Disease Detection

BRUSSELS, Belgium--(BUSINESS WIRE)--April 22, 2004-- The International Diabetes Federation (IDF) announced today that the Federation supports the International Symposium on Albuminuria. The conference, titled "The Role Of Albuminuria In Health And Disease; Predicting Outcomes And Targets For Therapy," will take place in New York City May 16-18, and will provide an opportunity for medical and research experts from around the world to gather and discuss the role of albuminuria as an independent marker and therapy target for the early detection and prevention of kidney and cardiovascular disease. Since first taking up the diabetes cause in 1950, the IDF has evolved into an umbrella organization of 183 member associations in 142 countries. This event is being organized by the National Kidney Foundation and the International Society of Nephrology. "Our mission is to enhance the lives of those affected by diabetes. By 2025, the number of people with diabetes is expected to more than double in Africa, the Eastern Mediterranean and Middle East, and South-East Asia, and rise by 20% in Europe, 60% in North America, 85% in South and Central America and 75% in the Western Pacific. The human and economic costs of diabetes could be significantly reduced by investing in prevention, particularly early detection, in order to avoid the onset of diabetic complications," said Pierre Lefebvre, president of the International Diabetes Federation. "In supporting this meeting we feel our member associations will benefit from the exchange of invaluable clinical data thus improving diabetes care around the globe."

Fifty percent of people with type 1 diabetes will develop microalbuminuria, the earliest sign of diabetic nephropathy. Numerous studies show that early detection and treatment of kidney disease can slow, halt or even reverse its progression.

The Symposium is also supported by the American Society of Nephrology, the Juvenile Diabetes Research Foundation and the American Diabetes Association. This three-day event is made possible by AusAm Biotechnologies, Inc.

References:

Diabetes Atlas second edition, International Diabetes Federation, 2003

Diabetes and Kidney Disease: Time to Act, International Diabetes Federation, 2003

About the International Diabetes Federation

The International Diabetes Federation is the only global advocate for people with diabetes and their healthcare providers. As a non-governmental organization in official relations with the World Health Organization and the Pan American Health Organization, the federation's mission is to work with member associations to enhance the lives of people with diabetes. Since first taking up the diabetes cause in 1950, the International Diabetes Federation has evolved into an umbrella organization of 183 member associations in 142 countries. More information is available at www.idf.org.

About AusAm Biotechnologies, Inc.

AusAm is a biotechnology research and development company commercializing both diagnostic and therapeutic products to identify and treat major diseases. AusAm's recently FDA-cleared diagnostic for the detection of intact albumin in urine is the first direct test to measure a potential indicator of the beginning stages of kidney disease, and is currently offered by several reference laboratories and hospitals in the United States.

Contact:

Schwartz Communications, Inc. Wendy Williams or Amy Kramer, 781-684-0770 email: ausam@schwartz-pr.com or

International Diabetes Federation Anne Pierson, +32-2-543 1623 email: anne@idf.org

Source: AusAm Biotechnologies



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES